Acorda Therapeutics Inc. (ACOR) Jumps 5.68% on January 25

Equities Staff  |

Acorda Therapeutics Inc. (ACOR) was among the biggest gainers on the Russell 2000 for Monday January 25 as the stock popped 5.68% to $40.16, representing a gain of $2.16 per share. Some 757,410 shares traded hands on 6,373 trades, compared with an average daily volume of 713,777 shares out of a total float of 43.16 million. The stock opened at $37.68 and traded with an intraday range of $40.57 to $36.85.

After today's gains, Acorda Therapeutics Inc. reached a market cap of $1.73 billion. Acorda Therapeutics Inc. has had a trading range between $44.99 and $25.50 over the last year, and it had a 50-day SMA of $39.14 and a 200-day SMA of $34.08.

The stock has a P/E Ratio of 760.

Acorda Therapeutics Inc is a biopharmaceutical company. It is engaged in the identification, development & commercialization of novel therapies for the treatment of neurological disorders.

Acorda Therapeutics Inc. is based out of Ardsley, NY and has some 489 employees. Its CEO is Ron Cohen.

For a complete fundamental analysis analysis of Acorda Therapeutics Inc., check out’s Stock Valuation Analysis report for ACOR. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










What Is Petrolithium?

MGX Minerals explains the advantages of petrolithium and how they are helping to solve future problems today.

Emerging Growth

The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd through its subsidiary operates as a cannabinoid-based research and development company in Canada.